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Effects of xanthine amine congener on hypoxic 
coronary resistance and venous and epicardial 
adenosine concentrations 
Darrell R Sawmiller, Joel Linden, and Robert M Berne 
Objective: The aim was to define the contributions of interstitial and vascular adenosine in regulating coronary 
vascular resistance during hypoxia. To help in the assessment of adenosine in the vasodilator response, a potent 
adenosine receptor antagonist, xanthine amine congener (XAC), was used to block adenosine receptors. 
Methods: Seven isolated guinea pig hearts were perfused at constant flow with Krebs buffer. Coronary vascular 
resistance was determined during normoxia (95% O2 j and mild hypoxia (60% 0,) in the absence or presence 
of 200 or 400 nM XAC. Interstitial fluid was sampled by the epicardial disc technique and the interstitial 
concentration of XAC (ISF[XAC]) was determined directly by a radioreceptor assay or as tritiated XAC. Venous 
and epicardial concentrations of adenosine were determined by high performance liquid chromatography. In six 
additional experiments, the vasodilator effect of 1 FM intracoronary adenosine was measured in the absence 
or presence of 100 or 200 nM XAC. Results: Mild hypoxia decreased coronary resistance by 37(SEM 4)% in 
the absence of XAC and 26(5j% or 17(4)70 in the presence of 200 or 400 nM XAC, respectively. rs~[xAC] 
rapidly equilibrated with [XAC] in the arterial perfusate or venous effluent. XAC 400 nM markedly increased 
( ~ ~ 0 . 0 5 )  the hypoxic levels of venous and epicardial fluid adenosine from 49(19j and 251(42) nM to 75(11) 
and 495(48) nM, respectively. XAC 100-200 nM almost completely prevented the vasodilatation induced by 1 
pM intracoronary adenosine. Conclusions: Adenosine mediates at least 54% of hypoxic vasodilatation. XAC 
rapidly equilibrates within the myocardial interstitial space and, as a result of blocking adenosine receptors, 
increases interstitial and venous adenosine concentrations. Increases in interstitial adenosine may partially 
overcome the adenosine receptor blockade by XAC, thereby reducing the effectiveness of XAC in attenuating 
the hypoxic vasodilatation. XAC attenuates intracoronary adenosine induced vasodilatation (mediated by 
endothelial adenosine receptors) much more effectively than it attenuates hypoxic vasodilatation, underscoring 
the minimal role played by the endothelial receptors in hypoxic vasodilatation. 
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t is well recognised that hypoxia induces coronary 
vasodilatation and that adenosine plays a role in this I vasodilator response.'-3 Adenosine is released from the 
myocytes of hypoxic hearts and reaches vasoactive 
concentrations in the interstitial fluid and coronary venous 
effluent.'-6 In addition, hypoxic coronary vasodilatation has 
been shown to be attenuated by adenosine deaminase '-' 
and the potent adenosine receptor antagonists 8-phenyl- 
theophylline'" and BW-A1433.6 In each of these studies, the 
attenuation was incomplete, suggesting that hypoxic vaso- 
dilatation may not be solely mediated by adenosine. It is also 
possible that vascular adenosine deaminase or adenosine re- 
ceptor antagonists do not penetrate sufficiently into the inter- 
stitial fluid to completely deaminate interstitial adenosine or 
block interstitial adenosine receptors.'' I ?  Furthermore, 
myocardial adenosine release may increase during adenosine 
receptor blockade and partially overcome the competitive 
blockade." '' Indeed, adenosine appears to act as a mediator 
in the feedback system which couples myocardial oxygen 
requirements to coronary flow (oxygen supply).'-' During 
adenosine receptor blockade, the feedback loop is opened and 
adenosine production may increase further to maintain 
When using a competitive adenosine receptor antagonist 
to evaluate the role of adenosine in hypoxic coronary 
vasodilatation, it is useful to know the interstitial con- 
centrations of both adenosine and the antagonist during 
normoxia and hypoxia. In previous studies,' ' "  the interstitial 
concentration of neither adenosine nor the antagonist was 
determined. The present study was undertaken to determine 
more clearly the extent to which adenosine is involved in 
hypoxic coronary vasodilatation in the isolated guinea pig 
heart. To this end, we studied the effect of intracoronary 
infusion of one of the most potent adenosine receptor 
antagonists, xanthine amine congener (XAC)," on hypoxic 
coronary vasodilatation, and simultaneously measured the 
vascular and interstitial concentrations of adenosine and 
XAC. In addition, we compared the relative effectivenesses 
of XAC in attenuating hypoxic and intracoronary adenosine 
induced vasodilatations. The results enabled us to estimate 
the relative contributions played by adenosine receptors on 
coronary vascular smooth muscle" and vascular endo- 
thelium,lb-" respectively, in hypoxic vasodilatation. 
Methods 
coronary flow. If any of these possibilities occur, then Pecfusion protocol 
adenosine might mediate a greater proportion of the total 
hypoxic than that shown in the studies using 
adenosine deaminase or receptor antagonists. 
Mature Hartley Winea Pigs (300-400 S body weight) were 
anaesthetised with 100 mg.kg-' ketamine and 20 rng.kg-' xylazine 
intramuscularly. A tracheostomy was performed and the animals were 
artificially ventilated. After thoracotomy, the caval veins were ligated 
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and the hearts were rapidly excised and immersed in ice cold perfusion 
solution. The aorta was cannulated and the coronary arteries were 
retrogradely perfused with Krebs-Henseleit buffer containing (in 
mmo1,litre-I): NaCl 119, KCl 4.7, CaC12 2.5, MgS04 1.2, NaHC03 25, 
KHzPOl 1.2, glucose 5.5, and pyruvate 2. The perfusion solution was 
equilibrated with 95% 02/5% COZ, maintained at a temperature of 37°C 
and pH of 7.4. The hearts were paced at 4 Hz by ventricular stimulation 
and perfused at a constant flow rate of 9.6(SEM 0.2) ml.min-l.g-' 
throughout the entire experiment, which yielded an initial perfusion 
pressure of 64( 1) mm Hg. A drain was introduced into the left ventricle 
via the mitral valve and placed in the cardiac apex to prevent 
accumulation of Thebesian drainage. Aortic pressure was monitored via 
a side port in the aortic cannula 5 mm above the level of the aortic 
valve. The pulmonary artery was cannulated for the collection of the 
coronary venous effluent for quantification of adenosine by high 
performance liquid chromatography (HPLC) and XAC by a radio- 
receptor assay, as described below. Arterial samples were collected 
from a side port in the aortic cannula 2 cm above the aortic valve. 
Coronary vascular resistance was determined continuously by dividing 
the perfusion pressure (in mm Hg) by the coronary flow rate 
(mlmin-'&) and expressed in peripheral resistance units (prug'). All 
surgical procedures conformed with the guidelines of the University of 
Virginia animal research committee and were in accordance with 
National Institute of Health policies and the Guide for the care and 
use of laboratory animals (NIH Publication No 85-23, revised 
1985). 
Experimental protocol 
Effect of XAC on hypoxic vasodilatation (n = 7) - After 
equilibrating the hearts for 30 min with buffer gassed with 95% 02/5% 
COz, hypoxia was initiated by perfusing the hearts with buffer gassed 
with 60% 02/35% NJ5% COz. Epicardial transudate, arterial perfusate, 
and venous effluent samples for determination of adenosine and XAC 
concentrations were obtained before and 1-7 min after the induction of 
hypoxia. Coronary resistance was measured before and 7 min after the 
induction of hypoxia (after the time when resistance reached a steady 
state). After the samples were collected, the hearts were re-equilibrated 
for 30 min by perfusion with the normoxic buffer and then XAC 
(Research Biochemicals) was infused into a side port of the aortic 
cannula. The rate of infusion was adjusted to equal lll0Oth of the 
coronary flow rate and to yield a final concentration of 200 nM in the 
perfusion buffer. After 5 min of XAC infusion, hypoxia was initiated 
while maintaining the XAC infusion, and arterial, venous, and 
epicardial samples were obtained. The hearts were then re-equilibrated 
with the normoxic buffer. XAC was infused to yield a concentration of 
400 nM, and hypoxia was initiated once again. The XAC solution used 
for infusion was prepared from a stock solution containing 1 mM XAC 
and 0.1 N NaOH. This stock was diluted in perfusion buffer and filtered 
(0.45 pm) before infusion. In three experiments, the effect of vehicle 
alone (20 or 40 pN NaOH) on hypoxic vasodilatation was de- 
termined. 
Effect of decreases in coronary perfusion pressure on 
venous adenosine concentration (n = 4) - Since hypoxia simultaneously 
decreases coronary perfusion pressure and increases venous adenosine 
concentration under the constant flow condition, a decrease in perfusion 
pressure alone could cause an increase in adenosine concentration. We 
determined if this is the case by assessing the effect of decreases in 
perfusion pressure alone induced by the coronary vasodilator pinacidil 
on venous adenosine concentration. Hearts were perfused at a constant 
flow rate of 9.1(0.3) rnl.min-l& and after equilibration they were 
perfused in a cumulative fashion with pinacidil at 0.1-3 pM 
concentrations. Venous effluent samples were collected after 7 min 
perfusion at each concentration. 
Effect of XAC on adenosine induced Vasodilatation (n = 6)  
- After equilibration, adenosine was infused at a concentration (1 pM) 
that has been shown to produce near maximum vasodilatation.' I 9  The 
hearts were then allowed to return to baseline resistance, perfused with 
100 or 200 nM XAC, and adenosine infusion was repeated after 5 min 
of the XAC perfusion. 
Epicardial fiuid sampling 
Epicardial fluid was sampled with porous nylon discs as described 
previously! 2o Epicardial discs 6 mm in diameter (MicroSep Magna 
Nylon 66 Membrane Filters, Micron Separation Inc) with a pore size 
of 0.45 pm were preweighed dry and then soaked in Krebs-Henseleit 
perfusate before application to the heart for a 1 min contact period. The 
epicardial sample collected before hypoxia consisted of four discs 
placed on the left ventricle in two consecutive pairs. This sam le was 
used for determination of interstitial adenosine concentration.* *' The 
epicardial sample collected during hypoxia consisted of eight discs, in 
four consecutive pairs. Four discs were used for determination of 
interstitial adenosine concentration and four for determination of XAC 
concentration. After removal, the discs were reweighed to determine the 
volume of absorbed interstitial fluid, sealed inside sample tubes and 
stored at -80°C until they were analysed for adenosine or XAC. 
Series 1. 
Series 2. 
Series 3. 
l? 
Quantification of adenosine by HPLC 
Adenosine was analysed as described previou~ly.~ l 3  Four discs 
acquired at each time point were collectively thawed and placed in 40 
p1 of distilled water to elute the sample. The samples were filtered 
through 0.22 p,m filters with the aid of centrifugation and placed in 
HPLC tubes. Of this sample, 175 pl were injected onto a C-18 reverse 
phase column (Supelco, 5 p) and eluted with a buffer gradient (100 mM 
m 2 P 0 4 ,  1% methanol, pH 5.53 at time zero, to 100 mM KH,P04, 
25% methanol, pH 5.58 at 45 min) at a flow of 1.3 ml.min-'. Ultraviolet 
absorbance was continuously monitored at 254 nm. Adenosine peaks 
were quantified by comparison of peak areas with those of standards. 
To calculate the epicardial purine concentration, the sample concentra- 
tions were multiplied by the sample dilution factor: (400 pl)/sample 
volume (pl). Venous effluent samples (175 PI) were injected directly 
on the HPLC column for analysis. 
Quanti$cation of XAC by radioreceptor assay 
The four discs acquired during each hypoxic period for XAC analysis 
were collectively thawed and placed in 500 p1 of methanol to elute the 
XAC. The discs from each sample were then placed in 500 p1 
additional methanol, and the total sample was filtered, evaporated to 
dryness, and reconstituted in 175 p1 Krebs buffer for XAC analysis. 
The arterial perfusate and venous effluent samples were analysed 
directly or diluted 1 to 10 with Krebs buffer. 
The method used for the quantification of XAC was modified from 
a standard radioligand binding assay for Al adenosine receptors, which 
has been described previously.** Aliquots (25 pl) of a bovine brain 
membrane suspension (0.05-0.1 mg protein) in HE buffer [ l o  mM 
N-2-hydroxyethylpiperazine-N-2-ethanesulphonic acid (HEPES), 1 .O 
mM ethylenediaminetetra-acetic acid (EDTA), 0.1 mM benzamidine, 
0.02% NaN3, pH 7.4]22 containing adenosine deaminase (10 U.rn1-I; 
Boehringer Mannheim) was mixed with 50 pl of sample or standard 
(0.5-10000 nM XAC in Krebs buffer). In some cases, XAC standards 
were also added to discs, processed as described above and assayed. 
Carrier-free 1251-N6-aminobenzyladenosine ("'I-ABA; 25 fmol in 25 pl, 
50 nCi)** in HE buffer containing 0.01% 3-[(3-~holamidopropyl)- 
dimethylammonio]-1-propanesulphonate (CHAPS) and 50 mM MgC12 
were then added. After a 2 h incubation, membranes were filtered over 
Whatman GFIC glass fibre filters presoaked with 0.3% poly- 
ethylenimine and then washed three times with ice cold buffer 
containing 10 mM tris (hydroxy-methyl) aminomethane hydrochloride 
(Tris-HCI) and 1 mM MqCII, pH 7.4. Radioactivity trapped on the 
filters representing bound 251-ABA was counted in a gamma counter. 
The XAC concentrations in the samples were determined based on their 
competition for Iz5I-ABA binding compared to that of the standards. 
There is little interference with this assay from endogenous materials 
in the epicardial fluid or venous effluent. Endogenous adenosine is 
eliminated by the addition of adenosine deaminase in the assay and 
inosine does not appreciably bind to the A, receptors in bovine brain 
membranes. In addition, samples collected in the absence of XAC 
perfusion did not produce detectable displacement of radioligand from 
the receptors. 
In order to further determine if vascular XAC equilibrates with the 
interstitial fluid, two hearts were perfused with tritiated XAC and the 
concentrations of tritiated XAC in arterial perfusate, venous effluent, 
and epicardial disc samples were determined. The tritiated XAC 
(specific activity -100 Ci.mmo1) was a gift from Richard Green 
(University of Illinois, Chicago, USA) and purified by thin layer 
chromatography as described p rev iou~ ly .~~  About 0.9 pCi of the 
purified tritiated XAC was mixed with 3 ml of 20 pM XAC and infused 
intra-arterially at a rate equal to l/lOOth of the coronary flow rate. This 
yielded a final concentration of 200 nM and 3 nCim-'  of tritiated XAC. 
Aliquots (100 pl) of the arterial perfusate or venous effluent samples 
were placed in 5 ml liquid scintillation fluid (CytoScint; ICN 
Biomedicals) and counted with a Beckman LS 8100. The epicardial 
disc samples were placed directly in scintillation fluid and counted. The 
levels of tritiated XAC in these samples were expressed as dpmm-l 
after correcting for quench and counter efficiency. The levels of tritiated 
XAC in the epicardial and venous effluent samples were then expressed 
as a fraction of the levels in the arterial perfusate. 
Statistical analysis 
All values shown are mean(SEM). Statistical comparisons between 
individual means were made with analysis of variance followed by the 
Fisher LSD test. A probability of p<O.O5 indicated a significant 
difference between values. 
Results 
The first series of experiments was designed to evaluate the 
effects of 200 or 400 nM XAC on hypoxic vasodilatation. 
The effect of XAC on coronary vascular resistance (fig 1)  
was similar to its effect on coronary perfusion pressure 
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(table I). As shown in fig 1, hypoxia reduced coronary 
vascular resistance in the absence or presence of XAC 
(p < 0.05). XAC did not significantly alter normoxic 
coronary resistance (p>O.O5) but 200 and 400 nM XAC 
increased hypoxic coronary resistance (p < 0.05). In addition. 
hypoxic coronary resistance in the presence of 400 nM XAC 
was greater than in the presence of 200 nM XAC (p < 0.05). 
Hypoxia decreased coronary vascular resistance by 37(SEM 
4)% in the absence of XAC and by 26(5)% and 17(4)% in 
the presence of 200 or 400 nM XAC, respectively. 
The effect of XAC vehicle (20 or 40 pN NaOH) on hypoxic 
vasodilatation is also shown in table I. Hypoxia reduced 
coronary perfusion pressure in the absence or presence of 20 
or 40 pN NaOH (p < 0.05) and neither concentration of NaOH 
significantly altered the vasodilatation. 
The concentrations of XAC in the arterial perfusate, 
venous effluent, and epicardial fluid before and during 
perfusion of the heart with XAC were determined directly by 
radioreceptor assay (n = 5 )  or indirectly as tritiated XAC 
(n=2).  During perfusion with 200 or 400 nM XAC. 
concentrations of XAC were 182(66) and 429(121) nM in 
the arterial perfusate, respectively. 186(55) and 430( 108) nM 
in the venous effluent, respectively. and 33335) and 
571(107) nM in the epicardial fluid respectively. In two 
additional experiments. we perfused the heart with 200 nM 
tritiated XAC and determined the levels of tritiated XAC in 
IC- Normoxia I Hypoxia i 
 -i 
Before XAC 200 400 
Perfusate [XACI (nM) 
Figure 1 Corona? \sascitlar resistance (CVR) during normoxiu 
arid hypoxia in the absence or presence of 200 or 400 nM XAC. 
*Significant difference from the CVR during preceding normo.ria 
( p  < 0.05): +significant difference from CVR during preceding 
hypoxia ([? < 0.05); I? = 7. 
Table I Coronary peifimon preswre (CPP) and J l o ~  during 
normom and hvpona i n  the absence or preyence of XAC or vehicle 
(NaOH) Vnluec cue meanc(SEM) 
Coronrrn per$ision pressure (mm H g )  
Norm0 rrn H\poxia 
200 nM XAC 66(2) 48(3)*+ 
Coronary Rou = 9 O(0 3 )  ml n u n  g 
Before XAC 6 3 2 )  400)" 
400 nM XAC 67/31 55(3)*+ 
Before ~ e h i c k  69(7) 
20 pN NaOH 6 3 3 )  
10 pH NaOH 70(4) 
Coronary flow =!, 910.3) ml niin-'  g-I 
*Significanf differences from CPP during preceding norrnoxia under the 
same concentrations of XAC or vehicle (p < 0.05): tsignificant differences 
from CPP during preceding hypoxia (p <0.05). 
each of these fluid compartments, The levels of tritiated 
XAC in the epicardial fluid was 77-100% of that in the 
arterial perfusate or venous effluent. 
Figure 2 shows venous and epicardial adenosine con- 
centrations during normoxia and hypoxia in the absence or 
presence of XAC. Hypoxia significantly increased venous 
adenosine concentration in the absence or presence of 200 or 
400 nM XAC. However, the mild degee of hypoxia used in 
this study did not produce a statistically significant increase 
in epicardial fluid adenosine concentration. Four hundred 
nanomolar XAC significantly increased the hypoxic venous 
and normoxic and hypoxic epicardial concentrations of 
adenosine. 
Since the increase in venous adenosine concentration 
shown during hypoxia might be caused by the associated 
decrease in coronary perfusion pressure, we determined 
whether or not decreases in perfusion pressure alone increase 
venous adenosine concentration. Hearts were perfused with 
0.1-3 pM pinacidil which decreased coronary perfusion 
pressure by 2-50% (fig 3). Pinacidil decreased perfusion 
pressure to a level which is similar to that produced by 
hypoxia. However, in contrast to the effect of hypoxia, 
pinacidil did not alter venous adenosine concentration. 
The effect of XAC on intracoronary adenosine induced 
vasodilatation (series 3 experiments) is shown in table I1 and 
fig 4. Adenosine decreased coronary perfusion pressure and 
vascular resistance in the absence of XAC and these 
vasodilatations were attenuated by 100 nM XAC and 
blocked by 200 nM XAC. 
0 Normoxia I Hypoxia 
100 
*t 
80 i-" T 
600 - 
/ B  
500 
- 1  i 
0 
T 
400; 
- 
.- j 2oo~~I 
," 100 
0 
Before XAC 
i 200 
t 
t T  
400 
Perfusate [XACI (nM) 
Figure 2 The levels of adenosine in coronary venous efjluent (A)  
and epicardial trunsudate (B)  during normoxia and hypoxia in the 
absence or presence of 200 or 400 nM XAC. 
*Signijicant differences from udenosine levels during the preceding 
normoxiu (p < 0.05); tsignificant differences from the correspond- 
ing adenosine levels in the absence of XAC (p < 0.05); n = 7. 
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Figure 3 Venous adenosine concentration and percent decrease 
in coronary perjiusion pressure (%A CPP) induced by 0.1-3 (LLM 
pinacidil. All concentrations of pinacidil induced a signijicant 
decrease in CPP (p < 0.05) but did not alter the venous adenosine 
concentration. Coronary perfusion pressure and venous adenosine 
concentration before infusion of pinacidil were 64(SEM 2 )  mm Hg 
and 11(3) nM, respectively. Standard errors of the venous 
adenosine concentrations ([Ado]) are within the area of the 
symbols; n = 4. 
Table II Coronary perfusion pressure (CPP) and flow before and 
during intracoronary infusion of adenosine (lab M) in the absence 
or presence of XAC. Values are means(SEM). 
Coronary perfusion pressure (mm Hg)  
Before adenosine During adenosine 
Before XAC 6 W )  
100 nM XAC 63(3) 
200 nM XAC 63(3) 
Coronary flow = 10.3(0.4) rnl.min-’.g-’ 
*Significant differences from CPP preceding the adenosine infusion 
(p < 0.05); ?significant difference from CPP during adenosine infusion in the 
absence of XAC (p < 0.05). 
10 Before During adenosine (lo4 M) I 
* 7 5  0 
” 
Before XAC 
(6)  
I 100 
200 
Perfusate [XACI (nM) 
Figure 4 Coronary vascular resistance (CVR) before and during 
lab M intracoronary adenosine in the absence or presence of 100 
or 200 nM XAC. 
*Signijcant differences from the CVR preceding the adenosine 
infusion ( p  < 0.05); tsignijicant difference from the CVR during 
adenosine infusion in the absence of XAC (p < 0.05); numbers of 
experiments in parentheses. 
Discussion 
The present study used the potent adenosine receptor 
antagonist, XAC, to determine more clearly the role of 
adenosine in hypoxic myocardial vasodilatation. This is the 
first study to measure simultaneously vascular and interstitial 
levels of adenosine and a competitive adenosine receptor 
antagonist, as well as coronary resistance, during myocardial 
hypoxia. The results indicate that XAC rapidly equilibrates 
between the vascular and interstitial spaces of the isolated 
guinea pig heart. XAC increased hypoxic coronary resistance 
but did not alter the normoxic resistance, suggesting that 
adenosine plays a role in hypoxic but not normoxic vascular 
resistance. In addition, XAC attenuated 54% of hypoxic 
vasodilatation, confirming the results of other studies which 
show that adenosine deaminase’ or adenosine receptor 
antagonist? lo partially reverse hypoxic vasodilatation. The 
present results also show that XAC substantially increases 
epicardial and venous adenosine concentrations. Increases in 
myocardial adenosine concentration might overcome to 
some extent the adenosine receptor blockade by XAC, 
reducing the effectiveness of XAC in increasing hypoxic 
coronary resistance and attenuating the hypoxic vasodilata- 
tion. Therefore the effect of XAC on this vasodilatation 
probably underestimates the true extent of the involvement 
of adenosine in this vasodilator response. 
Hypoxic vasodilatation is thought to be mediated in part 
by interstitial adenosine produced by myocardial cells and 
acting on adenosine receptors located on the abluminal 
surface of the vascular smooth muscle.’-3 If this is the case, 
then the ability of adenosine deaminase or receptor 
antagonists to attenuate the vasodilatation depends on the 
ability of these compounds to enter the interstitial fluid. It 
has recently been shown that intracoronary infusion of 
adenosine deaminase into the isolated guinea pig heart does 
not result in rapid equilibration of this enzyme between the 
vascular and interstitial spaces of the heart.” This is 
predictable, based on the high molecular weight of this 
enzyme (36 m a ) .  The weak adenosine receptor antagonist, 
theophylline, required 20 minutes to equilibrate between the 
vascular and interstitial spaces of the heart in anaesthetised 
dogs in vivo.” In the present study performed with isolated 
guinea pig hearts, 6-12 minutes of intracoronary infusion of 
XAC caused the epicardial concentration of XAC to reach 
levels which in fact tended to be greater than in the arterial 
perfusate. The precise reason for this “concentrating” effect 
is not presently known. For example, it is not known if XAC, 
a weak base, is trapped within the interstitial fluid by binding 
to structures such as adenosine receptors or sialic acid 
residues on the surface of cell membranes. While our results 
may be at odds with those showing slow equilibration of 
theophylline,” the discrepancy may be explained in part by 
the fact that saline perfusion markedly increases vascular 
pe~meability.’~ The present study shows that in the 
Langendorff perfused guinea pig heart, the inability of XAC 
to cause total blockade of hypoxic vasodilatation is not due 
to the inability of this compound to reach the interstitial fluid 
and equilibrate within it. 
Our results confirm other studies which show that 
adenosine receptor blockade increases myocardial adenosine 
 concentration^.'^ l4 In the present study (fig 2), 400 nM XAC 
increased venous and epicardial adenosine concentrations by 
about 25 and 200-250 nM, respectively. It is unlikely that 
these increases alone overcame by a significant extent the 
adenosine receptor blockade by 400 nM XAC. As shown in 
fig 4, 100-200 nM XAC were sufficient to attenuate greatly 
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or block the vasodilatation produced by 1 pM adenosine. 
However, XAC might also increase midmyocardial and 
endocardial adenosine concentrations. Endocardia1 adenosine 
concentration in the normoxic resting guinea pig heart starts 
at 3-5 PM.'~ If XAC doubles this interstitial concentration, 
as it did the epicardial concentration (fig 2), then the increase 
might be sufficient to overcome at least partially the receptor 
blockade by XAC. The precise reason for the XAC induced 
increases in adenosine concentration is not known. It has 
been hypothesised that adenosine acts as a mediator in the 
feedback system which couples myocardial oxygen re- 
quirements to coronary flow (oxygen supply).' During 
adenosine receptor blockade, the feedback loop is opened 
and adenosine production may necessarily increase further to 
maintain total coronary flow and distribution. 
It is notable that hypoxia alone did not increase the 
epicardial adenosine concentration (fig 2). This is surprising 
since hypoxia is known to be a potent stimulus for increasing 
myocardial adenosine concentration.14 In addition, the 
guinea pig hearts used in this study were perfused by 
constant flow, which should favour the interstitial ac- 
cumulation of adenosine and other vasoactive metabolites 
during hypoxia. It is possible that hypoxic vasodilatation is 
not necessarily associated with global increases in interstitial 
adenosine concentration, particularly during mild hypoxia. 
Mild hypoxia might induce significant increases in endo- 
cardial and midmyocardial adenosine concentration without 
altering the epicardial concentration. In addition, the 
epicardial disc technique used in this study may not be 
sufficiently precise to detect the small increase in interstitial 
adenosine produced by this mild degree of hypoxia. 
Unfortunately, the effects of hypoxia on endocardial and 
midmyocardial adenosine levels were not determined in the 
present study but remain an important area for future 
investigation. 
In contrast to the lack of effect of mild hypoxia on 
epicardial adenosine concentration, fig 2 shows that this level 
of hypoxia produced significant increases in venous 
adenosine Concentration. It is therefore possible that blood 
vessels themselves are a significant source of aden~sine'~ 36 
and that this adenosine acts locally on the coronary 
vasculature to mediate hypoxic vasodilatation. The increase 
in venous adenosine concentration shown in the present 
study was indeed caused by hypoxia and not by the hypoxia 
induced decrease in coronary perfusion pressure alone. As 
shown in fig 3 .  similar decreases in perfusion pressure 
induced by pinacidil did not increase venous adenosine 
concentration. 
Another interesting finding is that 100-200 nM XAC 
greatly attenuated or blocked the vasodilatation induced by 
1 p M  intracoronary adenosine (fig 4). but 200 nM XAC did 
not produce maximum attenuation of the hypoxic vaso- 
dilatation (fig 1). Indeed, 400 nM XAC produced more 
attenuation of the hypoxic vasodilatation than did 200 nM 
XAC. Recent evidence indicates that within the range of 
adenosine concentrations which cause coronary vasodilata- 
tion, the action of intracoronary adenosine is primarily 
limited to the endothelium." 2' Perfusion of isolated guinea 
pig hearts with 0.01-1 pM "C or 'H adenosine causes 
preferential labelling of the endothelium as assessed by 
autoradiography or by measurement of the radioactivity in 
endothelial cells detached from the hearts with collagenase/ 
trypsin.Ix In addition, perfusion with 6 or 12 pM adenosine 
causes maximal vasodilatation' l9  but did not raise the adeno- 
sine levels in the interstitial fluid.*' Therefore, the present 
results appear to indicate that 100-200 nM XAC is sufficient 
to attenuate greatly or block the vasodilatation induced by 
activation of vascular endothelial adenosine receptors with 1 
pM adenosine. The fact that the effect of XAC disassociate 
adenosine induced and hypoxia induced vasodilatation 
appears to suggest that endothelial adenosine receptors are 
not primarily responsible for hypoxic vasodilatation. It is 
likely that hypoxic vasodilatation is mediated by adenosine 
receptors located on vascular smooth muscle as originally 
proposed.'-3 It is notable also that endothelial and vascular 
smooth muscle cells seem to possess different adenosine 
receptor subtypes with different affinities for aden~sine.'~ 
Recent studies show that factors in addition to adenosine 
may also play a role in hypoxic coronary vasodilatation. 
These factors include prostaglandins,6 '' 29 ATP,30 ATP sen- 
sitive K'  channel^,^' 32 and endothelium derived nitric 
Further studies will be needed to determine 
how these compounds interact with each other and with 
adenosine to mediate hypoxic vasodilatation. 
In conclusion, the results from the present study indicate 
that: ( 1 )  adenosine mediates at least 54% of hypoxic 
vasodilatation in the isolated constant flow perfused guinea 
pig heart; ( 2 )  hypoxic vasodilatation may not necessarily be 
associated with global increases in interstitial adenosine 
concentration, particularly during mild hypoxia; ( 3 )  blockade 
of adenosine receptors by XAC increases the interstitial 
concentration of endogenous adenosine, which may partially 
overcome the blockade; (4) XAC more effectively attenuates 
the vasodilatation induced by intracoronary adenosine than 
that caused by hypoxia. The reason for this preferential 
effectiveness of XAC is unclear, but it appears to underscore 
the minimal role played by vascular endothelial adenosine 
receptors in hypoxic coronary vasodilatation. 
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